A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.

NCT01752023 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Low Accrual

Conditions

Non-small Cell Lung Cancer Metastatic

Interventions

DRUG: Cisplatin + Gemcitabine with SUBATM-itraconazole
DRUG: Cisplatin + Gemcitabine

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins